Loading clinical trials...
Loading clinical trials...
This single-center, investigator-initiated prospective clinical study aims to evaluate the impact of the Force Feedback function of the da Vinci 5 (dV5) robotic surgical system on surgical skill acquisition and intraoperative safety during robot-assisted radical prostatectomy (RARP). Although robotic surgery is well established in urology, the absence of tactile sensation remains a major limitation of previous systems. The new dV5 platform incorporates real-time haptic (force) feedback, potentially reducing excessive tissue traction and improving surgical precision. A total of 60 patients with clinically localized prostate cancer will be enrolled at Samsung Medical Center. Two surgeons (one faculty and one trainee) will each perform 30 RARP cases, with Force Feedback ON/OFF randomly assigned for each case. The primary endpoints are (1) mean traction force and (2) total instrument path length during seminal vesicle dissection. Secondary endpoints include surgical performance metrics (time, clutch counts), intraoperative safety, postoperative complications, and patient-reported outcomes (IPSS, IIEF-5, EPIC-CP, ICIQ-UI SF). Data will be analyzed using mixed-effects models accounting for surgeon-level random effects. This study seeks to provide quantitative evidence on how Force Feedback enhances surgical learning efficiency, precision, and patient safety in next-generation robotic prostate surgery.
This prospective, single-institution, investigator-initiated clinical trial investigates how the Force Feedback (haptic sensing) technology in the da Vinci 5 (dV5) robotic surgery platform influences technical skill acquisition and safety in robot-assisted radical prostatectomy (RARP). The study is conducted at Samsung Medical Center (Seoul, Korea) under the supervision of Professor Seong Soo Jeon and Dr. Jiwoong Yu from the Department of Urology. Robotic-assisted surgery has revolutionized minimally invasive prostate cancer treatment, but conventional robotic systems (e.g., da Vinci Xi) lack tactile feedback, forcing surgeons to rely solely on visual cues. This limitation may lead to excessive force application and increase the risk of tissue injury. The dV5 system introduces a Force Feedback mechanism that allows surgeons to feel real-time resistance transmitted through the robotic arms. Preclinical reports suggest this reduces applied forces by up to 40-50% and improves precision, especially during the learning phase. However, objective clinical data quantifying these benefits are limited. The present trial will enroll 60 patients diagnosed with clinically localized prostate cancer (cT1-T3a, N0, M0) eligible for RARP. Two surgeons-a senior faculty (expert) and a urology resident (trainee)-will each perform 30 RARP cases. For each surgery, the Force Feedback function will be randomly assigned (ON vs. OFF) while maintaining identical operative conditions. The seminal vesicle dissection step is chosen as the standardized assessment phase since it is technically demanding yet safe for educational evaluation. Primary endpoints are: Mean traction force applied to tissue (N) Total instrument path length (m) during seminal vesicle dissection Secondary endpoints include: Surgical performance metrics: operative time, clutch counts, peak force, efficiency indicators, and cumulative sum (CUSUM) learning curves. Safety parameters: estimated blood loss, complications (graded by Clavien-Dindo), hospital stay, and biochemical recurrence. Patient-reported outcomes: urinary, sexual, and overall quality of life assessed by validated questionnaires (IPSS, IIEF-5, EPIC-CP, ICIQ-UI SF). Procedural efficiency metrics such as lens-cleaning frequency and suction count. All operations will be video-recorded and digitally logged using dV5 Case Insight software, which captures objective performance indicators (OPIs) including instrument trajectory, applied force, and clutch frequency. Statistical analysis will use linear mixed-effects models with Force Feedback status and case sequence as fixed effects, and surgeon ID as a random effect, allowing adjustment for intra-surgeon correlations and learning effects. Safety monitoring follows institutional IRB and KGCP guidelines. All adverse events (AEs) and device deficiencies will be documented, with serious adverse events (SAEs) reported within 24 hours. Standard perioperative management and intraoperative supervision by experienced faculty will ensure patient safety. This study is designed as a pilot exploratory analysis that integrates human performance data, haptic sensor output, and clinical outcomes. Findings will offer the first objective evidence on how haptic feedback influences both novice and expert robotic surgeons in terms of force modulation, precision, efficiency, and safety. The results may guide the optimization of training curricula and inform the development of future robotic platforms incorporating tactile intelligence.
Age
19 - No limit years
Sex
MALE
Healthy Volunteers
No
Samsung Medical Center
Soeul, South Korea
Start Date
January 1, 2026
Primary Completion Date
June 30, 2026
Completion Date
December 31, 2027
Last Updated
February 25, 2026
60
ESTIMATED participants
Force-feedback on
DEVICE
Forece-feedback off
DEVICE
Lead Sponsor
Seong Soo Jeon
NCT04550494
NCT05691465
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions